Literature DB >> 11286846

Effects of Motexafin gadolinium on tumor metabolism and radiation sensitivity.

S Xu1, K Zakian, H Thaler, C Matei, A Alfieri, Y Chen, J A Koutcher.   

Abstract

PURPOSE: Experiments were undertaken to determine if metabolic changes induced by Motexafin gadolinium (Gd-Tex(+2), XCYTRIN) predict time intervals between drug and radiation wherein there is enhancement of radiation efficacy. METHODS AND MATERIALS: We evaluated the effect of Gd-Tex(+2) on tumor metabolism and on tumor growth using a mouse mammary carcinoma model and (31)P nuclear magnetic resonance (NMR) experiments. Response to therapy was evaluated based on time for the tumor to regrow to pretreatment size and also tumor doubling time.
RESULTS: (31)P NMR experiments indicated that Gd-Tex(+2) effected tumor energy metabolism during the first 24 hours postadministration. A decrease in phosphocreatine was noted at 2 (p < 0.04), 6 (p < 0.006), and 24 (p < 0.001) hours post Gd-Tex(+2). A decrease in nucleoside triphosphates was noted only at 2 hours (p < 0.02), with subsequent recovery at 6 hours. Phosphocreatine in control (saline treated) tumors showed a significant decrease only at 24 hours (p < 0.01). Irradiation at 2 and 6 hours post Gd-Tex(+2) induced an enhanced effect compared to radiation alone as measured by analyzing the growth curves, maximum tumor volumes, and the time for the tumors to regrow to their initial volumes. Irradiation at 24 hours post Gd-Tex(+2) induced a modest enhancement in tumor growth delay compared to radiation alone. DISCUSSION: NMR spectroscopy may be useful for monitoring tumor metabolism after treatment with Gd-Tex(+2) and administering radiation during the time of maximal efficacy of Gd-Tex(+2).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286846     DOI: 10.1016/s0360-3016(00)01566-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

Review 1.  Whole-brain radiation therapy in breast cancer patients with brain metastases.

Authors:  Cyrus Chargari; François Campana; Jean-Yves Pierga; Lionel Védrine; Damien Ricard; Sylvestre Le Moulec; Alain Fourquet; Youlia M Kirova
Journal:  Nat Rev Clin Oncol       Date:  2010-07-13       Impact factor: 66.675

2.  Six degrees of separation: the oxygen effect in the development of radiosensitizers.

Authors:  Bryan T Oronsky; Susan J Knox; Jan Scicinski
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

Review 3.  The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective.

Authors:  Jonathan L Finlay; Stergios Zacharoulis
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

4.  Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial.

Authors:  Derek R McHaffie; Pierre Chabot; Anne Dagnault; John H Suh; Marie-Andrée Fortin; Eric Chang; Robert Timmerman; Luis Souhami; John Grecula; Abdenour Nabid; Chris Schultz; Maria Werner-Wasik; Laurie E Gaspar; David Brachman; Tarak Mody; Minesh P Mehta
Journal:  J Neurooncol       Date:  2011-04-27       Impact factor: 4.130

5.  Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study.

Authors:  Kristin A Bradley; Tianni Zhou; Rene Y McNall-Knapp; Regina I Jakacki; Adam S Levy; Gilbert Vezina; Ian F Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-22       Impact factor: 7.038

6.  Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin) in CD1 mice following intravenous and intraperitoneal injection.

Authors:  G W Boswell; D R Miles; P A Thiemann; M Mesfin
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

7.  Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins.

Authors:  Longhua Qiu; Feng Zhang; Yaoping Shi; Zhibin Bai; Jianfeng Wang; Yonggang Li; Donghoon Lee; Christopher Ingraham; Xiaoyuan Feng; Xiaoming Yang
Journal:  Radiology       Date:  2015-11-24       Impact factor: 11.105

8.  MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain.

Authors:  Genevieve N Wu; Judith M Ford; Jeffry R Alger
Journal:  J Neurooncol       Date:  2006-03-18       Impact factor: 4.130

9.  The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trial.

Authors:  Andrew M Evens; William G Spies; Irene B Helenowski; David Patton; Stewart Spies; Borko D Jovanovic; Sarah Miyata; Elizabeth Hamilton; Daina Variakojis; Jun Chen; Louie Naumovski; Steven T Rosen; Jane N Winter; Richard A Miller; Leo I Gordon
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

Review 10.  Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies.

Authors:  Andrew M Evens; Lakshmi Balasubramanian; Leo I Gordon
Journal:  Curr Treat Options Oncol       Date:  2005-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.